| abstract |
A novel fusion polypeptide in which FGFR3 polypeptides are fused with other polypeptides in a plurality of bladder cancer-derived cells and lung cancer cells is identified and isolated by carrying out a detailed study on the expression, over-amplification, mutation and translocation of FGFR coding genes in various cancer cells . By using the fusion polypeptide of the present invention as a biomarker in the treatment of cancer by the FGFR inhibitor, it is possible to prevent the occurrence of side effects in the treatment with the FGFR inhibitor in advance and to control the treatment sun so as to obtain the best therapeutic effect It becomes possible to do individualized medical treatment. |